ReviewClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System.
Review in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 68 citations in OpenAlex.
- A case of immune thrombocytopenia complicated by catastrophic antiphospholipid antibody syndrome and subsequent intramuscular haemorrhage.Journal of medical case reports · 2026Article
- C4b-binding protein as an antigenic target in the pathogenesis of antiphosphatidylethanolamine autoantibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Plasma proteomics identifies early markers of endothelial and inflammatory activation associated with dengue disease severity in children.medRxiv : the preprint server for health sciences · 2026Article
- Cardiovascular Involvement in Systemic Lupus Erythematosus: Focus on Arrhythmias.Diagnostics (Basel, Switzerland) · 2026Review
- Enhanced type I interferon signature in primary APS patients is associated with thrombocytopenia.Frontiers in immunology · 2026Article
- Investigating the predictive role of serum amyloid A and its association with immunological and coagulation biomarkers in recurrent pregnancy loss.The Libyan journal of medicine · 2025Article
- Cardiac Involvement in Systemic Lupus Erythematosus.Reviews in cardiovascular medicine · 2025Review
- Pathogenic and Regulatory Roles of Fibrinolytic Factors in Autoimmune Diseases.Current issues in molecular biology · 2025Review
- Activated Complement System's Impact in Antiphospholipid Syndrome Thrombosis: From Pathophysiology to Treatment.Journal of clinical medicine · 2025Review
- Association of Anticardiolipin Antibody in Myocardial Infarction: A Systematic Review and Meta-Analysis.Cureus · 2025Review
- Antiphospholipid antibodies are associated with increased levels of selected oxidative stress biomarkers.Thrombosis journal · 2025Article
- Association between antivimentin/cardiolipin antibodies and pregnancy loss in pregnant women with at least one spontaneous miscarriage.BMC immunology · 2025Article
- From Circulating Biomarkers to Polymorphic Variants: A Narrative Review of Challenges in Thrombophilia Evaluation.Journal of clinical medicine · 2025Review
- Review
- Antiphospholipid syndrome in pregnancy: a comprehensive literature review.BMC pregnancy and childbirth · 2025Review
- Ubiquitin-proteasome system: a potential participant and therapeutic target in antiphospholipid syndrome.Frontiers in immunology · 2025Review
- Neurovascular complications of antiphospholipid syndrome: a narrative review.Arquivos de neuro-psiquiatria · 2024Review
- Using Doppler ultrasound to assess fetal cardiac function and pregnancy outcomes in obstetric antiphospholipid syndrome pregnancies: a case-control study.Archives of gynecology and obstetrics · 2024Observational
- Antiphospholipid Antibody Testing in a Maximum Care Hospital: Method-Dependent Differences.Journal of clinical medicine · 2024Article
- Assessing the Impact of Hematological Changes in Pregnancy on Maternal and Fetal Death: A Narrative Review.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by a hypercoagulability associated to vascular thrombosis and/or obstetric morbidity, is caused by the presence of antiphospholipid antibodies such as lupus anticoagulant, anti-β-2-glycoprotein 1, and/or anticardiolipin antibodies. In the obstetrical APS, antiphospholipid antibodies induce the production of proinflammatory cytokines and tissue factor by placental tissues and recruited neutrophils. Moreover, antiphospholipid antibodies activate the complement system which, in turn, induces a positive feedback leading to recruitment of neutrophils as well as activation of the placenta. Activation of these cells triggers myometrial contractions and cervical ripening provoking the induction of labor. In thrombotic and obstetrical APS, antiphospholipid antibodies activate endothelial cells, platelets, and neutrophils and they may alter the multimeric pattern and concentration of von Willebrand factor, increase the concentration of thrombospondin 1, reduce the inactivation of factor XI by antithrombin, increase the activation of factor XII, and reduce the activity of tissue plasminogen activator with the subsequent production of plasmin. All these effects result in less permeable clots, denser, thinner, and with more branched fibrin fibers which are more difficult to lysate. As a consequence, thrombosis, the defining clinical criterion of APS, complicates the clinical course of the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.